Lactose India Ltd Stock Price Today (NSE: LACTOSE)
Fundamental Score
Lactose India Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Lactose India Ltd share price today is ₹101.85, down 4.68% on NSE/BSE as of 3 August 2026. Lactose India Ltd (LACTOSE) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of ₹130.11 (Cr). The 52-week high for LACTOSE share price is ₹136.70 and the 52-week low is ₹76.01. At a P/E ratio of 21.47x, LACTOSE is currently trading below its industry average P/E of 34.89x. The company has a Return on Equity (ROE) of 9.81% and a debt-to-equity ratio of 0.96.
Lactose India Ltd Share Price Chart — NSE/BSE Historical Performance
Lactose India Ltd share price chart: 3.46% return over the past month. 52-week high ₹136.70, 52-week low ₹76.01.
Lactose India Ltd — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹105.70 | ₹109.55 | ₹101.75 | ₹104.60 | 4.70K (Cr) | |
| ₹103.05 | ₹110.00 | ₹103.00 | ₹106.85 | 13.73K (Cr) | |
| ₹97.00 | ₹107.50 | ₹97.00 | ₹105.10 | 23.01K (Cr) | |
| ₹98.15 | ₹101.00 | ₹96.80 | ₹98.90 | 858.00 (Cr) | |
| ₹100.00 | ₹102.00 | ₹98.15 | ₹99.05 | 4.79K (Cr) | |
| ₹99.00 | ₹102.75 | ₹98.65 | ₹101.45 | 13.19K (Cr) | |
| ₹101.50 | ₹101.50 | ₹99.10 | ₹100.55 | 1.07K (Cr) | |
| ₹101.00 | ₹101.45 | ₹98.60 | ₹100.95 | 11.22K (Cr) | |
| ₹107.00 | ₹107.00 | ₹102.20 | ₹103.00 | 2.38K (Cr) | |
| ₹100.15 | ₹105.95 | ₹100.00 | ₹103.35 | 10.53K (Cr) |
Lactose India Ltd — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹105.95 | ₹110.00 | ₹95.00 | ₹104.60 | -1.27% | |
| ₹115.00 | ₹118.00 | ₹100.00 | ₹103.90 | -9.65% | |
| ₹113.05 | ₹136.45 | ₹102.45 | ₹114.45 | +1.24% | |
| ₹83.00 | ₹124.90 | ₹80.20 | ₹113.07 | +36.23% | |
| ₹96.00 | ₹99.99 | ₹76.01 | ₹80.41 | -16.24% | |
| ₹98.89 | ₹111.85 | ₹94.02 | ₹95.51 | -3.42% | |
| ₹103.80 | ₹109.00 | ₹94.00 | ₹96.20 | -7.32% | |
| ₹126.70 | ₹130.75 | ₹96.55 | ₹102.60 | -19.02% | |
| ₹119.85 | ₹136.00 | ₹101.25 | ₹128.00 | +6.80% | |
| ₹131.65 | ₹131.65 | ₹111.20 | ₹115.90 | -11.96% | |
| ₹108.05 | ₹136.70 | ₹108.05 | ₹125.80 | +16.43% | |
| ₹99.05 | ₹120.00 | ₹87.00 | ₹112.02 | +13.09% |
AI Research Briefing
Powered by Gemini · 2026-04-04
Historically high-growth pharma micro-cap with recent profit deceleration and balance sheet concerns.
Lactose India Ltd (LACTOSE) - Initiating Coverage Macro backdrop
- Strong historical sales growth
- Potential for margin expansion
- Pharma sector tailwinds
- New product launches
- Debt reduction
- Improved free cash flow
- High debt/equity ratio
- Low interest coverage
- Promoter pledging
Neutral; Promoter holding steady, no FII interest, minimal DII presence.
Pharmaceutical sector experiencing moderate growth.
No major company-specific news in the last 3 weeks
Poor; profits not converting well to cash.
Monitor for improved profitability and cash flow generation over the next 3-6 months.
Primary Thesis Risk
High debt and low cash flow pose significant risks.
For educational purposes only. Not investment advice. Consult a SEBI-registered advisor before investing.
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
Lactose India Ltd Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Lactose India Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of LACTOSE across key market metrics for learning purposes.
Positive Indicators
8 factors identified
Strong Operating Margins (15.44%)
Observation: Healthy 5-year operating margins indicate pricing power and cost control.
Analysis: OPM >15% suggests operational efficiency and competitive advantages.
Attractive Valuation (P/E: 21.47 vs Industry: 34.89)
Observation: Trading at discount to industry peers.
Analysis: P/E below industry average may present value opportunity.
Robust Profit Growth (193.75%)
Observation: Strong year-over-year profit expansion demonstrates business momentum.
Analysis: Profit growth >20% indicates effective execution and market opportunity capture.
Strong Revenue Growth (64.82%)
Observation: Healthy sales growth indicates market demand and execution capability.
Analysis: Revenue growth >15% suggests strong market position and growth potential.
Consistent Growth Track Record (36.11% CAGR)
Observation: Strong 5-year sales compound annual growth rate.
Analysis: Consistent sales CAGR >12% demonstrates sustainable growth model.
Excellent EPS Growth (33.37% CAGR)
Observation: Outstanding 5-year earnings per share compound growth.
Analysis: EPS CAGR >15% indicates strong wealth creation potential.
Strong Profit Growth Track Record (34.76% CAGR)
Observation: Consistent 5-year profit compound annual growth rate.
Analysis: Profit CAGR >15% demonstrates scalable business model.
Balanced Promoter Holding (53.64%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment.
Risk Factors
4 factors identified
Below-Average Return on Equity (9.81%)
Observation: Returns on equity are below industry benchmarks.
Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.
Limited Institutional Interest (FII+DII: 0.62%)
Observation: Low institutional participation may affect liquidity.
Analysis: Limited institutional interest may indicate size constraints or visibility issues.
High Share Pledging Risk (26.07%)
Observation: Significant promoter share pledging creates potential overhang.
Analysis: High pledging levels may create selling pressure during market downturns.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.
Lactose India Ltd vs Pharmaceuticals Peers
Peer Comparison - Pharmaceuticals
Compare Lactose India Ltd with 10 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
Lactose India LtdLactose India L...Selected✓ LACTOSE • 524202 | 52.8/100 | ₹101.85₹102 | ₹130.11₹130.11 | 21.47Average 21.5 Average | 9.81%Poor 9.81% Poor | 11.29%Average 11.29% Average | 0.96Good 1.0 Good | 34.76%Excellent 34.76% Excellent | 36.11%Excellent 36.11% Excellent | 0.00% |
Sun Pharmaceutical Industries LtdSun Pharmaceuti... SUNPHARMA • 524715 | 66.4/100 | ₹1990.50₹1991 | ₹468821.49₹468821.49 | 37.73Average 37.7 Average | 15.95%Good 15.95% Good | 20.53%Excellent 20.53% Excellent | 0.06Excellent 0.1 Excellent | 16.75%Excellent 16.75% Excellent | 11.78%Good 11.78% Good | 0.82% |
Divis Laboratories LtdDivis Laborator... DIVISLAB • 532488 | 56.3/100 | ₹8056.00₹8056 | ₹193163.97₹193163.97 | 73.64Average 73.6 Average | 16.53%Good 16.53% Good | 21.96%Excellent 21.96% Excellent | 0.00Excellent 0.0 Excellent | 5.71%Good 5.71% Good | 8.67%Good 8.67% Good | 0.41% |
Torrent Pharmaceuticals LtdTorrent Pharmac... TORNTPHARM • 500420 | 51.4/100 | ₹5122.80₹5123 | ₹169902.02₹169902.02 | 77.52Average 77.5 Average | 27.43%Excellent 27.43% Excellent | 15.19%Good 15.19% Good | 1.79Average 1.8 Average | 12.07%Good 12.07% Good | 11.80%Good 11.80% Good | 0.76% |
Cipla LtdCipla Ltd... CIPLA • 500087 | 40.2/100 | ₹1473.20₹1473 | ₹116131.81₹116131.81 | 30.51Average 30.5 Average | 11.60%Average 11.60% Average | 15.49%Good 15.49% Good | 0.02Excellent 0.0 Excellent | 9.94%Good 9.94% Good | 8.01%Good 8.01% Good | 0.90% |
Zydus Lifesciences LtdZydus Lifescien... ZYDUSLIFE • 532321 | 74.1/100 | ₹1078.30₹1078 | ₹115375.77₹115375.77 | 21.26Average 21.3 Average | 21.25%Excellent 21.25% Excellent | 21.14%Excellent 21.14% Excellent | 0.46Excellent 0.5 Excellent | 18.77%Excellent 18.77% Excellent | 12.45%Good 12.45% Good | 0.09% |
Lupin LtdLupin Ltd... LUPIN • 500257 | 83.4/100 | ₹2415.00₹2415 | ₹113976.53₹113976.53 | 20.04Average 20.0 Average | 28.68%Excellent 28.68% Excellent | 29.93%Excellent 29.93% Excellent | 0.29Excellent 0.3 Excellent | 37.02%Excellent 37.02% Excellent | 13.02%Good 13.02% Good | 0.72% |
Mankind Pharma LtdMankind Pharma ... MANKIND • 543904 | 61.5/100 | ₹2469.60₹2470 | ₹105053.91₹105053.91 | 52.29Average 52.3 Average | 13.12%Average 13.12% Average | 13.50%Average 13.50% Average | 0.39Excellent 0.4 Excellent | 10.52%Good 10.52% Good | 18.10%Excellent 18.10% Excellent | 0.04% |
Dr Reddys Laboratories LtdDr Reddys Labor... DRREDDY • 500124 | 41/100 | ₹1148.10₹1148 | ₹102660.46₹102660.46 | 25.62Average 25.6 Average | 11.22%Average 11.22% Average | 13.04%Average 13.04% Average | 0.20Excellent 0.2 Excellent | 15.44%Excellent 15.44% Excellent | 12.09%Good 12.09% Good | 0.65% |
Aurobindo Pharma LtdAurobindo Pharm... AUROPHARMA • 524804 | 24.6/100 | ₹1580.20₹1580 | ₹90035.87₹90035.87 | 25.38Average 25.4 Average | 10.06%Average 10.06% Average | 12.80%Average 12.80% Average | 0.21Excellent 0.2 Excellent | 0.80%Average 0.80% Average | 6.32%Good 6.32% Good | 0.26% |
Laurus Labs LtdLaurus Labs Ltd... LAURUSLABS • 540222 | 34.1/100 | ₹1816.20₹1816 | ₹84016.75₹84016.75 | 93.94Average 93.9 Average | 18.30%Good 18.30% Good | 17.76%Good 17.76% Good | 0.48Excellent 0.5 Excellent | -1.89%Poor -1.89% Poor | 7.19%Good 7.19% Good | 0.13% |
Top Pharmaceuticals Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Sun Pharmaceutical Industries Ltd share price468821.49 Cr
- Divis Laboratories Ltd share price193163.97 Cr
- Torrent Pharmaceuticals Ltd share price169902.02 Cr
- Cipla Ltd share price116131.81 Cr
- Zydus Lifesciences Ltd share price115375.77 Cr
Lactose India Ltd PE Ratio History
Historical price-to-earnings ratio for LACTOSE — last 5 years
| Year | EPS (₹) | Price (₹) | P/E Ratio |
|---|---|---|---|
| FY 2024 | ₹5.39 | ₹214.55 | 39.8x |
P/E = year-end price ÷ diluted EPS from annual filings. Source: NSE/BSE via Bull Run.
Lactose India Ltd Quarterly Performance
Latest quarterly metrics for LACTOSE — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
64.82%
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
193.75%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
36.11%
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
34.76%
Compounded annual net profit growth over 5 years
Lactose India Ltd Technical Indicators
SMA 50, SMA 200, RSI and volume signals for LACTOSE — calculated from daily price history
Momentum is balanced — neither overbought nor oversold.
Technical indicators are for educational purposes only. Not investment advice.
Lactose India Ltd Financial Statements
Annual income statement, balance sheet and cash flow for Lactose India Ltd (LACTOSE) — sourced from NSE/BSE filings.
Loading Financial Statements...
Fetching financial data for Lactose India Ltd
About LACTOSE (Lactose India Ltd)
Lactose India Ltd is a pioneering force in the pharmaceutical landscape, carving a niche for itself through the intricate science of lactose-based formulations and a commitment to ...enhancing global health. The company meticulously crafts a diverse portfolio of pharmaceutical products, designed to meet a wide range of therapeutic needs. Their state-of-the-art manufacturing facilities are the heart of their operations, producing everything from essential lactose monohydrate, a fundamental ingredient in countless medications, to complex solid and liquid dosage forms. Lactose India's unwavering focus on quality and innovation underscores its position as a trusted supplier and manufacturer in the pharmaceutical domain. Beyond simply producing base ingredients, Lactose India Ltd expertly formulates both solid and liquid medicines with precision. This includes advanced methods like dry granulation for tablets, film coatings for easy swallowing, and specialized lacquer coatings for sustained release or enhanced stability. Their expertise ensures that each product meets the stringent requirements of the pharmaceutical industry, offering effective and reliable treatment options for patients across various medical conditions. Lactose India's commitment to producing these diverse dosage forms highlights their comprehensive approach to pharmaceutical manufacturing, catering to the evolving needs of healthcare professionals and patients alike. Furthermore, Lactose India Ltd stands out through its development of the active pharmaceutical ingredient (API), disaccharide lactulose. This specialized ingredient is pivotal in addressing various health issues, offering relief from constipation and potentially alleviating symptoms related to liver diseases like hepatitis and encephalopathy. Lactulose's therapeutic benefits also extend to promoting healthy intestinal microflora and supporting dental health. Lactose India's dedication to producing such a vital API reflects the company's dedication to expanding the frontiers of pharmaceutical solutions and enhancing health outcomes through innovative research and development.
Company Details
Key Leadership
Latest News
LACTOSE Share Price: Frequently Asked Questions
What is the current share price of Lactose India Ltd?
Lactose India Ltd (LACTOSE) trades at ₹101.85 on NSE and BSE. Market cap ₹130.11 (Cr). Educational data only.
What is the P/E ratio of Lactose India Ltd?
Lactose India Ltd has a P/E of 21.47x vs industry average 34.89x.
What is the Bull Run score for Lactose India Ltd?
Lactose India Ltd has a Bull Run score of 52.8/100 based on 25+ financial parameters.
Does Lactose India Ltd pay dividends?
Lactose India Ltd has a dividend yield of 0.00%. Past dividends don't guarantee future payments.
What is the ROE of Lactose India Ltd?
Lactose India Ltd has ROE of 9.81%. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of Lactose India Ltd?
Lactose India Ltd has debt-to-equity of 0.96.
Is Lactose India Ltd a good investment?
Bull Run gives Lactose India Ltd a score of 52.8/100. This is not investment advice — consult a SEBI-registered advisor.